218 related articles for article (PubMed ID: 21393879)
1. Utility of p63 immunohistochemical stain in differentiating urothelial carcinomas from adenocarcinomas of prostate.
Ud Din N; Qureshi A; Mansoor S
Indian J Pathol Microbiol; 2011; 54(1):59-62. PubMed ID: 21393879
[TBL] [Abstract][Full Text] [Related]
2. Placental S100 (S100P) and GATA3: markers for transitional epithelium and urothelial carcinoma discovered by complementary DNA microarray.
Higgins JP; Kaygusuz G; Wang L; Montgomery K; Mason V; Zhu SX; Marinelli RJ; Presti JC; van de Rijn M; Brooks JD
Am J Surg Pathol; 2007 May; 31(5):673-80. PubMed ID: 17460449
[TBL] [Abstract][Full Text] [Related]
3. Diagnostic utility of androgen receptor expression in discriminating poorly differentiated urothelial and prostate carcinoma.
Downes MR; Torlakovic EE; Aldaoud N; Zlotta AR; Evans AJ; van der Kwast TH
J Clin Pathol; 2013 Sep; 66(9):779-86. PubMed ID: 23775437
[TBL] [Abstract][Full Text] [Related]
4. Pseudopapillary features in prostatic adenocarcinoma mimicking urothelial carcinoma: a diagnostic pitfall.
Gordetsky J; Epstein JI
Am J Surg Pathol; 2014 Jul; 38(7):941-5. PubMed ID: 24503758
[TBL] [Abstract][Full Text] [Related]
5. Prostate-specific antigen, high-molecular-weight cytokeratin (clone 34betaE12), and/or p63: an optimal immunohistochemical panel to distinguish poorly differentiated prostate adenocarcinoma from urothelial carcinoma.
Kunju LP; Mehra R; Snyder M; Shah RB
Am J Clin Pathol; 2006 May; 125(5):675-81. PubMed ID: 16707367
[TBL] [Abstract][Full Text] [Related]
6. Immunohistochemical differentiation of high-grade prostate carcinoma from urothelial carcinoma.
Chuang AY; DeMarzo AM; Veltri RW; Sharma RB; Bieberich CJ; Epstein JI
Am J Surg Pathol; 2007 Aug; 31(8):1246-55. PubMed ID: 17667550
[TBL] [Abstract][Full Text] [Related]
7. The role of P501S and PSA in the diagnosis of metastatic adenocarcinoma of the prostate.
Sheridan T; Herawi M; Epstein JI; Illei PB
Am J Surg Pathol; 2007 Sep; 31(9):1351-5. PubMed ID: 17721190
[TBL] [Abstract][Full Text] [Related]
8. Immunophenotype of high-grade prostatic adenocarcinoma and urothelial carcinoma.
Genega EM; Hutchinson B; Reuter VE; Gaudin PB
Mod Pathol; 2000 Nov; 13(11):1186-91. PubMed ID: 11106075
[TBL] [Abstract][Full Text] [Related]
9. Primary mucin-producing urothelial-type adenocarcinoma of prostate: report of 15 cases.
Osunkoya AO; Epstein JI
Am J Surg Pathol; 2007 Sep; 31(9):1323-9. PubMed ID: 17721186
[TBL] [Abstract][Full Text] [Related]
10. Immunohistochemical expression of prostatic antigens in adenocarcinoma and villous adenoma of the urinary bladder.
Lane Z; Hansel DE; Epstein JI
Am J Surg Pathol; 2008 Sep; 32(9):1322-6. PubMed ID: 18670358
[TBL] [Abstract][Full Text] [Related]
11. Do HOXB13 and P63 have a role in differentiating poorly differentiated prostatic carcinoma from urothelial high-grade carcinoma?
Alshenawy HA; Saied E
APMIS; 2015 Sep; 123(9):772-8. PubMed ID: 26200506
[TBL] [Abstract][Full Text] [Related]
12. Immunohistochemical antibody cocktail staining (p63/HMWCK/AMACR) of ductal adenocarcinoma and Gleason pattern 4 cribriform and noncribriform acinar adenocarcinomas of the prostate.
Herawi M; Epstein JI
Am J Surg Pathol; 2007 Jun; 31(6):889-94. PubMed ID: 17527076
[TBL] [Abstract][Full Text] [Related]
13. Poorly differentiated adenocarcinomas of prostate versus high-grade urothelial carcinoma of the bladder: a diagnostic dilemma with immunohistochemical evaluation of 2 cases.
MartÃnez-RodrÃguez M; Ramos D; Soriano P; Subramaniam M; Navarro S; Llombart-Bosch A
Int J Surg Pathol; 2007 Apr; 15(2):213-8. PubMed ID: 17478786
[TBL] [Abstract][Full Text] [Related]
14. Immunohistochemical profile to distinguish urothelial from squamous differentiation in carcinomas of urothelial tract.
Gulmann C; Paner GP; Parakh RS; Hansel DE; Shen SS; Ro JY; Annaiah C; Lopez-Beltran A; Rao P; Arora K; Cho Y; Herrera-Hernandez L; Alsabeh R; Amin MB
Hum Pathol; 2013 Feb; 44(2):164-72. PubMed ID: 22995333
[TBL] [Abstract][Full Text] [Related]
15. Diagnostic utility of p63/P501S double sequential immunohistochemical staining in differentiating urothelial carcinoma from prostate carcinoma.
Srinivasan M; Parwani AV
Diagn Pathol; 2011 Jul; 6():67. PubMed ID: 21777423
[TBL] [Abstract][Full Text] [Related]
16. Role of p63 in differentiating morphologically ambiguous lesions of prostate.
Baig MK; Hassan U; Mansoor S
J Coll Physicians Surg Pak; 2012 Dec; 22(12):773-7. PubMed ID: 23217483
[TBL] [Abstract][Full Text] [Related]
17. Immunohistochemical staining characteristics of nephrogenic adenoma using the PIN-4 cocktail (p63, AMACR, and CK903) and GATA-3.
McDaniel AS; Chinnaiyan AM; Siddiqui J; McKenney JK; Mehra R
Am J Surg Pathol; 2014 Dec; 38(12):1664-71. PubMed ID: 24921643
[TBL] [Abstract][Full Text] [Related]
18. Diagnostic utility of immunohistochemical staining for p63, a sensitive marker of prostatic basal cells.
Weinstein MH; Signoretti S; Loda M
Mod Pathol; 2002 Dec; 15(12):1302-8. PubMed ID: 12481011
[TBL] [Abstract][Full Text] [Related]
19. Clinical utility of immunohistochemistry in the diagnoses of urinary bladder neoplasia.
Hodges KB; Lopez-Beltran A; Emerson RE; Montironi R; Cheng L
Appl Immunohistochem Mol Morphol; 2010 Oct; 18(5):401-10. PubMed ID: 20505509
[TBL] [Abstract][Full Text] [Related]
20. Nephrogenic adenoma: immunohistochemical evaluation for its etiology and differentiation from prostatic adenocarcinoma.
Xiao GQ; Burstein DE; Miller LK; Unger PD
Arch Pathol Lab Med; 2006 Jun; 130(6):805-10. PubMed ID: 16740031
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
